New Agents for Relapsed/Refractory Myeloma Impress in Early-Stage Clinical Trials High rates of deep, durable response with bispecific antibody, rapidly produced CAR T-cell agents Jun 05, 2023
Monoclonal Antibody Reduced Need For Transfusions in Low-Risk MDS Results suggest a "paradigm shift" in the treatment of anemia for these patients May 25, 2023
Cross-Border Collaboration Improves Survival in Pediatric Leukemia Patients 5-year OS increased to 100% in standard-risk ALL patients at a Tijuana hospital May 25, 2023
Adding Mylotarg to Chemo Fails to Boost Survival in NPM1-Mutated AML But trial detects "meaningful benefit" when it comes to relapse, editorialists say May 15, 2023
Allo-Transplant Tied to Better PFS in Advanced Cutaneous T-Cell Lymphomas Results will likely "encourage a practice change," editorialists say May 10, 2023
FLT3 Inhibitor Doubles Overall Survival in Acute Myeloid Leukemia Median OS improved from 15 months to nearly 32 months with quizartinib May 09, 2023
Mysterious White Blood Cell Disorder Not Just 'AIDS Without HIV' Idiopathic CD4 lymphocytopenia not so heterogenous after all May 03, 2023
Sodium Thiosulphate Not Much Help for Calciphylaxis in CKD Though used off-label for years, treatment isn't very beneficial Apr 26, 2023
Blinatumomab Plus Chemo Effective in Aggressive Infant ALL Low incidence of relapse after treatment "remarkable," researchers say Apr 26, 2023
Antibody-Drug Conjugate Gets FDA Thumbs Up for Untreated DLBCL Adding polatuzumab vedotin to a modified version of R-CHOP significantly improved PFS Apr 20, 2023
Novel Antibody Induces Durable Responses in Heavily Pretreated Myeloma Overall response rate of 90% in patients who received highest doses of REGN5459 Apr 18, 2023
Oral Drug Improves Sunlight Tolerance in Genetic Photosensitivity Disorders Dersimelagon significantly extended time to sun-related prodromal symptoms Apr 12, 2023
Blood Donor's Sex Makes No Difference for Survival Only difference seen was higher incidence of MRSA infection in recipients of female donor blood Apr 12, 2023
SYK Inhibitor Promising in Early Trial of Primary ITP Sovleplenib demonstrated "consistent response" as second-line treatment Apr 11, 2023
Major Survival Gain With Immunotherapy in Lymphomatoid Granulomatosis Median overall survival reached 20 years with interferon alfa-2b in low-grade disease Apr 05, 2023
FDA Greenlights First Drug for Rare Immunodeficiency Disease Activated PI3K-delta syndrome may have a new standard of care Mar 27, 2023
Make the Diagnosis: This Bump on His Nose is a Tricky Diagnosis A 52-year-old man visited his doctor for a new growth on his nose. Can you diagnosis the patient? Mar 27, 2023
Sam Neill's Rare Lymphoma The actor noticed swollen glands while on tour for "Jurassic World Dominion" Mar 23, 2023
Sickle Cell Disease Patients Miss Out on Decades of Life What effects might emerging therapies have on real-world survival? Mar 17, 2023
FDA Panel Endorses New First-Line Lymphoma Regimen POLARIX trial supports a favorable risk-benefit profile for polatuzumab vedotin, ODAC members say Mar 10, 2023
FDA Not Quite Sold on Polivy in Frontline Large B-Cell Lymphoma Regimen Ahead of ODAC meeting, agency reviewers suggest modest PFS results in POLARIX "raise uncertainty" Mar 07, 2023
Full-Dose Anticoagulation Again Favored for COVID Admissions Despite failures, FREEDOM trial supports mortality advantage in general ward use Mar 07, 2023
Cases of Breast Implant-Associated Lymphoma Continue to Accumulate More than 1,300 cases and 35 deaths, as reports of other implant-linked malignancies emerge Mar 06, 2023
'Winners' and 'Losers'; Mandated Sick Leave and Cancer Screening; More AI Advances News, features, and commentary about cancer-related issues Mar 03, 2023
Cancer Drugs That Didn't Work; Another HIV Cure; Kiss of Success With Mistletoe News, features, and commentary about cancer-related issues Feb 24, 2023
Gene Tx Shows Sustained Bleeding Control in Severe Hemophilia A at 2 Years Model predicts valoctocogene roxaparvovec could maintain mild hemophilia levels for 5 years Feb 23, 2023
Targeted Agents Go Head-to-Head for Newly Diagnosed Ph+ ALL Trial crowns a winner, but how relevant is it amid the changing therapeutic landscape for ALL? Feb 16, 2023
The 'Extreme' Story of How Two Game-Changing Cancer Drugs Came to Market New book by former Forbes senior editor pulls back the curtain on drug development Feb 13, 2023
Novel 'Off the Shelf' CAR-T Product Shows Promise in Myeloma Researchers say safety, efficacy of ALLO-715 comparable to autologous anti-BCMA products Feb 02, 2023
New Class of Factor VIII Replacement Therapy Prevents Bleeds in Severe Hemophilia A Weekly dosing with efanesoctocog alfa reduced annualized bleeding rate by 77% Jan 25, 2023
Inflammatory VEXAS Syndrome May Not Be So Uncommon Is new disease being missed by physicians? Jan 24, 2023
Epstein-Barr Virus Tracking After Liver Transplant May Cut Rare Complication Observational study provides suggestive evidence Jan 17, 2023
Off-the-Shelf T-Cell Therapy Effective Against Viral Infections After Allo-HCT Produced an antiviral response in 95% of patients with six different types of infection Jan 13, 2023
Zanubrutinib Shows Good Tolerance in BTK-Inhibitor Intolerant Malignancies Most patients had no recurrence of their original intolerance event Jan 10, 2023
Post-HSCT Brentuximab Vedotin Plus Nivolumab Highly Effective in Hodgkin Lymphoma However, toxic effects might limit the combination to the highest-risk patients Jan 10, 2023
Crystal Ball Cloudy for PI3K Inhibitors' Future in Hematology After a year of negative news, some caution about throwing out the baby with the bath water Jan 02, 2023
Early Win for Gene Therapy in Rare Form of SCID 10 infants were able to make their own T cells; safety good so far Dec 21, 2022
Anti-PD-1 Drugs Impress as Frontline Therapy for Early, Unfavorable Hodgkin's 3-year PFS of 99%, OS of 100% with nivolumab-chemo, high response rate with pembrolizumab Dec 16, 2022
New Regimen for GvHD Prophylaxis in Well-Matched Reduced-Intensity Allo-HCT Post-transplant cyclophosphamide, tacrolimus, and MMF reduces GvHD without higher relapse risk Dec 14, 2022
'Practice-Changing' Results With Zanubrutinib Versus Ibrutinib in CLL/SLL Significantly longer PFS with second-gen BTK inhibitor in relapsed/refractory disease Dec 14, 2022
